Are peptide YY (3-36), leptin, and tagatose approved for the treatment of obesity?

Updated: Jun 09, 2021
  • Author: Osama Hamdy, MD, PhD; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
  • Print

Peptide YY (3-36) is being developed as a nasal inhaler. Ongoing, preliminary phase 1 and 2 trials yielded encouraging results. [175, 176, 177]

Leptin is still used in cases of the rare obesity subclass of leptin-deficient obesity and lipodystrophy, but a study of the leptin analogue metreleptin in obese patients with diabetes found that metreleptin did not alter body weight. [178] The combination of metreleptin with pramlintide, however, led to enhanced weight loss in one study, [179] but a more recent randomized clinical trial on the combination of these 2 drugs was stopped because of safety concerns. [180]

Preliminary reports suggest the potential utility of agents that impede dietary carbohydrate absorption. Tagatose is one of the compounds in this class that is undergoing trials.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!